Informations/Recommandations/Veille bibliographique

ECMM Webinar Covid-19 associated aspergillosis : Programme 30 July, 18:00 –  19:30 hrs (CET):
Chairs: Martin Hoenigl and Oliver Cornely

The webinar is now available as an on demand recording for registered delegates. More information is available on https://www.ecmm.info/

Topics:

  1. Immunology  – Carol Garcia-Vidal
  2. Definitions – Paul Verweij
  3. Epidemiology: Europe and Beyond – Jon Salmanton-Garcia
  4. Azole resistance and its relevance for CAPA – Eelco Meijer
  5. Diagnosis – how it’s done now  – Jean Pierre Gangneux
  6. Point of Care diagnosis – soon reality?  – Lewis White  and Martin Hoenigl
  7. Treatment – Martin Hoenigl
  8. CAPA Management Guidance – Philipp Koehler

Manuscrits publiés sur le sujet entre le 1er avril et le 15 septembre 2020 :

1. Invasive fungal diseases during COVID-19:  We should be prepared. 
Gangneux JP, Bougnoux ME, Dannaoui E, Cornet M, Zahar JR. J Mycol Med. 2020 Apr 6:100971. doi: 10.1016/j.mycmed.2020.100971

2. COVID-19 Associated Pulmonary Aspergillosis. 
Koehler P, Cornely OA, Böttiger BW, Dusse F, Eichenauer DA, Fuchs F, Hallek M, Jung N, Klein F, Persigehl T, Rybniker J, Kochanek M, Böll B, Shimabukuro-Vornhagen A. Mycoses. 2020 Apr 27. doi: 10.1111/myc.13096.

3. Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. 
Blaize M, Mayaux J, Nabet C, Lampros A, Marcelin AG, Thellier M, Piarroux R, Demoule A, Fekkar A. Emerg Infect Dis. 2020 Apr 28;26(7). doi:10.3201/eid2607.201603.

4. Diagnosing COVID-19-associated pulmonary aspergillosis. 
Verweij PE, Gangneux JP, Bassetti M, Brüggeman RJM, Cornely OA, Koehler P, Lass-Flörl C, van de Veerdonk FL, Chakrabarti A, Hoenigl M. Lancet Microbe. 2020 May 08, DOI : https://doi.org/

5. Invasive pulmonary aspergillosis complicating COVID-19 in the ICU – A case report.
Prattes J, Valentin T, Hoenigl M, Talakic E, Reisinger AC, Eller P. Med Mycol Case Rep. 2020 May 11. doi: 10.1016/j.mmcr.2020.05.001.

6. COVID-19 Associated Pulmonary Aspergillosis.
van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. Am J Respir Crit Care Med. 2020 May 12. doi: 10.1164/rccm.202004-1038LE.

7. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19.
Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Lancet Respir Med. 2020 May 20:S2213-2600(20)30237-X. doi:10.1016/S2213-2600(20)30237-X.

8. COVID-19-associated invasive pulmonary aspergillosis.
Rutsaert L, Steinfort N, Van Hunsel T, Bomans P, Naesens R, Mertes H, Dits H, Van Regenmortel N. Ann Intensive Care. 2020 Jun 1;10(1):71.

9. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series.
Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T.  Version 2. Crit Care. 2020 Jun 5;24(1):299.

10. Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report.
Meijer EFJ, Dofferhoff ASM, Hoiting O, Buil JB, Meis JF.  J Fungi (Basel). 2020 Jun 6;6(2):E79.

11. Bacterial and fungal infections among patients with SARS-CoV-2 pneumonia.
Antinori S, Galimberti L, Milazzo L, Ridolfo AL. Infez Med. 2020 Jun 1;28(suppl 1):29-36.

12. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion.
Verweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Calandra T, Clancy CJ, Cornely OA, Chiller T, Depuydt P, Giacobbe DR, Janssen NAF, Kullberg BJ, Lagrou K, Lass-Flörl C, Lewis RE, Liu PW, Lortholary O, Maertens J, Martin-Loeches I, Nguyen MH, Patterson TF, Rogers TR, Schouten JA, Spriet I, Vanderbeke L, Wauters J, van de Veerdonk FL.  Intensive Care Med.2020 Jun 22.

13. Markers for Treatment Monitoring and Diagnosis in Invasive Mold Infection; COVID-19 Associated Pulmonary Aspergillosis (CAPA)—From Immunology to Treatment.
Arastehfar, A.; Carvalho, A.; van de Veerdonk, F.L.; Jenks, J.D.; Koehler, P.; Krause, R.; Cornely, O.A.; S. Perlin, D.; Lass-Flörl, C.; Hoenigl, M., on behalf of the ECMM Working Group Immunologic J. Fungi 2020, 6, 91.

14. COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges. Mohamed A, Rogers TR, Talento AF. J Fungi (Basel). 2020 Jul 22;6(3):E115.

16. Confronting and mitigating the risk of COVID-19 Associated Pulmonary Aspergillosis (CAPA).
Armstrong-James D, Youngs J, Bicanic T, Abdolrasouli A, Denning DW, Johnson E, Mehra V, Pagliuca T, Patel B, Rhodes J, Schelenz S, Shah A, van de Veerdonk FL, Verweij PE, White PL, Fisher MC. Eur Respir J. 2020 Jul 23:2002554.

17. Late histopathologic characteristics of critically ill COVID-19 patients: Different phenotypes without evidence of invasive aspergillosis, a case series.
Flikweert AW, Grootenboers MJJH, Yick DCY, du Mée AWF, van der Meer NJM, Rettig TCD, Kant MKM. J Crit Care. 2020 Jul 8;59:149-155.

18. Detection of Invasive Pulmonary Aspergillosis in COVID-19 with Non-directed Bronchoalveolar Lavage.
an Biesen S, Kwa D, Bosman RJ, Juffermans NP. Am J Respir Crit Care Med. 2020 Jul 15.

19. Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to categorize Aspergillosis in ICU Patients? A Monocentric Experience.
Gangneux JP, Reizine F, Guegan H, Pinceaux K, Le Balch P, Prat E, Pelletier R, Belaz S, Le Souhaitier M, Le Tulzo Y, Seguin P, Lederlin M, Tadié JM, Robert-Gangneux F. J Fungi (Basel). 2020 Jul 10;6(3):E105.

20. Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients.
Lamoth F, Glampedakis E, Boillat-Blanco N, Oddo M, Pagani JL. Clin Microbiol Infect. 2020 Jul 10:S1198-743X(20)30412-2.

21. COVID-19 and fungal co-infections: We must keep them in mind.
Agrifoglio A, Cachafeiro L, Figueira JC, Añón JM, García de Lorenzo A.J Mycol Med. 2020 Jul 4:101012.

22. Confirmed Invasive Pulmonary Aspergillosis and COVID-19: the value of postmortem findings to support antemortem management.
Santana MF, Pivoto G, Alexandre MAA, Baía-da-Silva DC, Borba MGDS, Val FA, Brito-Sousa JD, Melo GC, Monteiro WM, Souza JVB, Pinheiro SB, Ferreira LCL, Naveca FG, Nascimento VA, Corado ALG, Hajjar LA, Silva Neto JR, Siva GAV, Pasqualotto AC, Lacerda MVG. Rev Soc Bras Med Trop. 2020;53:e20200401.

23. Aspergillus fumigatus and pan-azole resistance: who should be concerned?
Wiederhold NP, Verweij PE. Curr Opin Infect Dis. 2020 Aug;33(4):290-297.

24. Fungal Co-infections Associated with Global COVID-19 Pandemic: A Clinical and Diagnostic Perspective from China.
Song G, Liang G, Liu W.  Mycopathologia. 2020 Jul 31:1–8. doi: 10.1007/s11046-020-00462-9.

25. Opportunistic Fungal Infections in the Epidemic Area of COVID-19: A Clinical and Diagnostic Perspective from Iran.
Salehi M, Ahmadikia K, Badali H, Khodavaisy S. Mycopathologia. 2020 Jul 31:1–5. doi:10.1007/s11046-020-00472-7

26. Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study.
Bartoletti M, and  PREDICO study group. Clin Infect Dis. 2020 Jul 28:ciaa1065. doi: 10.1093/cid/ciaa1065.

27. COVID-19 Associated Invasive Pulmonary Aspergillosis: Diagnostic and Therapeutic Challenges. Mohamed A, Rogers TR, Talento AF. J Fungi (Basel). 2020 Jul 22;6(3):E115. doi: 10.3390/jof6030115.

28. Invasive aspergillosis in patients with severe COVID-19 pneumonia.
Helleberg M, Steensen M, Arendrup MC. Clin Microbiol Infect. 2020 Aug 5:S1198-743X(20)30474-2.

29. Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19.
Thompson Iii GR, Cornely OA, Pappas PG, Patterson TF, Hoenigl M, Jenks JD, Clancy CJ, Nguyen MH.. Open Forum Infect Dis. 2020 Jun 19;7(7):ofaa242. doi: 10.1093/ofid/ofaa242.

30. Isolation of Aspergillus spp. in respiratory samples of patients with COVID-19 in a Spanish tertiary care hospital.
Falces-Romero I, Ruiz-Bastián M, Díaz-Pollán B, Maseda E, García-Rodríguez J; SARS-CoV-2 Working Group. Mycoses. 2020 Aug 4. doi: 10.1111/myc.13155.

31. Surveillance for COVID-19-associated pulmonary aspergillosis.
LAK Brown, J Ellis, R Gorton, S De, N Stone ; The Lancet Microbe, 2020

32. Fatal Coronavirus Disease 2019-associated Pulmonary Aspergillosis; A Report of Two

33. Cases and Review of the Literature.
Abdalla S, Almaslamani MA, Hashim SM, Ibrahim AS, Omrani AS. IDCases. 2020;22:e00935. doi:10.1016/j.idcr.2020.e00935.

34. Fatal aspergillosis complicating severe SARS-CoV-2 infection: A case report.
Schein F, Munoz-Pons H, Mahinc C, Grange R, Cathébras P, Flori P. J Mycol Med. 2020 Aug 20:101039. doi: 10.1016/j.mycmed.2020.101039.

35. Ventilator-associated pneumonia involving Aspergillus flavus in a patient with coronavirus disease 2019 (COVID-19) from Argentina.
Fernandez NB, Caceres DH, Beer KD, Irrazabal C, Delgado G, Farias L, Chiller TM, Verweij PE, Stecher D. Med Mycol Case Rep. 2020 Jul 5. doi: 10.1016/j.mmcr.2020.07.001.

36. A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU.
White PL, Dhillon R, Cordey A, Hughes H, Faggian F, Soni S, Pandey M, Whitaker H, May A, Morgan M, Wise MP, Healy B, Blyth I, Price JS, Vale L, Posso R, Kronda J, Blackwood A, Rafferty H, Moffitt A, Tsitsopoulou A, Gaur S, Holmes T, Backx M. Clin Infect Dis. 2020 Aug 29:ciaa1298. doi:10.1093/cid/ciaa1298.

37. Invasive Fungal Disease complicating COVID-19: when it rains it pours.
Hoenigl M. Clin Infect Dis. 2020 Sep 5:ciaa1342. doi: 10.1093/cid/ciaa1342.

38. Impact of negative air pressure in ICU rooms on the risk of pulmonary aspergillosis in COVID-19 patients.
Ichai P, Saliba F, Baune P, Daoud A, Coilly A, Samuel D.  Crit Care. 2020 Sep 1;24(1):538. doi: 10.1186/s13054-020-03221-w.

39. Incidence, risk factors, timing and outcome of influenza versus Covid-19 associated putative invasive aspergillosis.
Sarrazyn C, Dhaese S, Demey B, Vandecasteele S, Reynders M, Van Praet JT. Infect Control Hosp Epidemiol. 2020 Sep 9:1-7. doi: 10.1017/ice.2020.460.

40. Pulmonary aspergillosis in critically ill patients with Coronavirus Disease 2019 (COVID-19).
Dupont D, Menotti J, Turc J, Miossec C, Wallet F, Richard JC, Argaud L, Paulus S, Wallon M, Ader F, Persat F. Med Mycol. 2020 Sep 10:myaa078. doi: 10.1093/mmy/myaa078.

41. Bronchoscopy safety precautions for diagnosing COVID-19 associated pulmonary aspergillosis – a simulation study.
Koehler P, Cornely OA, Kochanek M. Mycoses. 2020 Sep 12. doi: 10.1111/myc.13183.

Actualités Congrès 2020-2021

Les principales annulations de réunions et de congrès:

  • ISHAM mars 2021 vraisemblablement reporté en mars 2022
  • Journée conjointe des sociétés françaises de pharmacologie et de mycologie du 26 mars 2020 : reportée
  • Journée franco-belge de mycologie médicale des 4 et 5 juin : reportée
  • Journée thématique Candida du 24 juin : reportée
  • Educational workshop de l’ECMM (initialement juin 2020 puis octobre 2020) reporté en avril 2021
  • Congrès annule SFP-SFMM de Cayenne en octobre 2020 reporté à une date à définir (date à définir avec les organisateurs et la SFP)

Les nouvelles dates:

  • Webinar SFMM-SFPT : 3 décembre 2020
  • Journée JC-JC : début 2021
  • Congrès SFMM-SFP 2022 à Rouen

Recommandations de la SFM

La SFMM incite à suivre les recommandations émises par la Société Française de Microbiologie (SFM) pour la gestion des échantillons biologiques afin que les pratiques soient standardisées et homogènes au sein d’un même établissement. Quelques adaptations locales liées aux organisations, aux ressources humaines ou équipements, et au niveau de circulation du virus SARS-Cov-2 doivent être discutées en interne avec vos référents hygiénistes et infectiologues.

Le lien pour télécharger la version actualisée de la fiche SFM validée par la DGS est le suivant : https://www.sfm-microbiologie.org

Actualités Epidémiologie du 23 avril 2020

La SFMM rappelle que différentes actions ont été mises en place autour du risque d’IFI et notamment d’aspergillose invasive chez les patients covid-19

  1. Alerte à la vigilance du HCSP qui recommande le suivi du risque fongique chez les patients Covid-19 en réanimation (Avis relatif à la prise en charge des cas confirmés d’infection au virus SARS-CoV21; 2020, https://www.hcsp.fr/
  2. La mise en place d’un registre d’IFI chez les patients Covid-19 au sein du CNRMA
  3. Le déploiement d’un protocole de recherche clinique multicentrique sur le screening systématique des patients de réanimations en SDRA intubés-ventilés soutenu par la SFMM : l’étude MY-CO-VID
  4. La mise en place d’un registre européen via l’ECMM auquel je vous invite à participer, sur le format des co-infections grippe/AI, piloté par Paul Verweij

Nos partenaires

Gold
Gold
Gold
Haut de page